Evidence map›Paper›PMID 40363763›Full record

ReviewMolecules (Basel, Switzerland)2025

Conditional Control of CRISPR/Cas9 Function by Chemically Modified Oligonucleotides.

Liangliang Wang, Yan Liu, Hongjun Song, Xue Zhang, Yang Wang

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liangliang WangSchool of Biological and Pharmaceutical Engineering, Lanzhou Jiaotong University, Lanzhou 730070, China.
Yan LiuKey Laboratory of Bioinorganic and Synthetic Chemistry (Sun Yat-sen University), Ministry of Education, Guangzhou 510006, China.ORCID 0000-0003-2649-2552
Hongjun SongKey Laboratory of Bioinorganic and Synthetic Chemistry (Sun Yat-sen University), Ministry of Education, Guangzhou 510006, China.
Xue ZhangKey Laboratory of Tropical Biological Resources of Ministry of Education and One Health Institute, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
Yang WangKey Laboratory of Bioinorganic and Synthetic Chemistry (Sun Yat-sen University), Ministry of Education, Guangzhou 510006, China.

Funding

the National Natural Science Foundation of China 22307107
6 · The paper itself

Abstract

The CRISPR (clustered regularly interspaced short palindromic repeats) system has emerged as a revolutionary gene-editing tool with immense potential in gene therapy, functional genomics, and beyond. However, achieving precise spatiotemporal control of gene editing in specific cells and tissues while effectively mitigating potential risks, such as off-target effects, remains a key challenge for its clinical translation. To overcome these limitations, researchers have developed innovative strategies based on chemical modifications of oligonucleotides to enhance the precision, efficiency, and controllability of CRISPR/Cas9-mediated gene editing. By introducing conditional responsive elements, such as photosensitive groups, small-molecule responsive units, and supramolecular structures, they have successfully achieved precise spatiotemporal and dose-dependent regulation of CRISPR/Cas9 function. This review provides a comprehensive overview of recent advancements in gRNA regulation strategies based on chemical modifications of oligonucleotides, discussing their applications in improving the efficiency, specificity, and controllability of CRISPR/Cas9 editing. We also highlight the challenges associated with the conditional control of gRNA and offer insights into future directions for the chemical regulation of gRNA to further advance CRISPR/Cas9 technology.

Indexed as

CRISPR-Cas SystemsGene EditingOligonucleotidesRNA, Guide, CRISPR-Cas SystemsAnimalsHumansOligonucleotidesRNA, Guide, CRISPR-Cas Systemschemical modificationconditional controlCRISPR/Cas9gene editingguide RNA (gRNA)

Identifiers

PMID40363763
PMCPMC12073707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.